US FDA's final guidance on the classification of products as drugs or devices contains some useful clarifications for industry, but experts remain concerned that the guidance contains too much room for the agency to continue its tendency of classifying products under the more heavily-regulated drug pathway.
FDA published the guidance, "Classification of Products as Drugs and Devices & Additional Product Classification Issues," on Sept. 26. It...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?